Clinical Trials Logo

Seizures clinical trials

View clinical trials related to Seizures.

Filter by:

NCT ID: NCT03123302 Completed - Clinical trials for Intracranial Aneurysm

Our Anesthesia Experience During MRI Scan

Start date: February 1, 2017
Phase:
Study type: Observational

In this study we aim to investigate the relationship between our anesthesia practice and post procedure complications after MRI scanning with sedation. This is a retrospective, single center observational study. All patients undergoing MRI scan during the study period will be included.

NCT ID: NCT03116828 Completed - Clinical trials for Epilepsy With Partial On-set Seizures

A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

Start date: July 7, 2017
Phase: Phase 4
Study type: Interventional

A study of a drug to be used in addition with another drug to treat adults with Uncontrolled Partial-onset Seizures

NCT ID: NCT03103425 Completed - Epilepsy Clinical Trials

Evaluation of StatNet Device for Electroencephalogram (EEG) Recordings

Start date: June 2009
Phase: N/A
Study type: Observational

The purpose of the study is to develop an emergency electroencephalogram (EEG) device, StatNet, that can be placed quickly by minimally-trained personnel and interpreted remotely for rapid identification of seizures.

NCT ID: NCT03083665 Completed - Epilepsy Clinical Trials

A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy

Start date: August 22, 2017
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (>=16 to 80 years of age) with partial seizures with or without secondary generalization despite current treatment with 1 or 2 concomitant antiepileptic drugs (AEDs) and to assess the safety and tolerability of BRV in subjects >= 16 years to 80 years of age.

NCT ID: NCT03071783 Completed - Clinical trials for Hypoxic Ischemic Encephalopathy

Intra-operative Feed Back on Traction Force During Vacuum Extraction: Safe Vacuum Extraction Alliance

SVEA
Start date: April 1, 2016
Phase: N/A
Study type: Interventional

The objective of the clinical investigation is to test whether intra-operative traction force feed back during vacuum extraction leads to a significant decrease in incidence of brain damage in neonates. By randomization, half of the vacuum extraction patients will be assigned to delivery using a new intelligent handle for vacuum extractions, and half will be assigned to conventional method without traction force measurement.

NCT ID: NCT03059381 Completed - Clinical trials for Primary Generalized Tonic-clonic Seizures

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures

FYC02T
Start date: August 1, 2016
Phase:
Study type: Observational

The objective of this study is to identify the following in adolescent epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa: 1. unknown adverse drug reactions (ADRs); 2. occurrence of ADRs; 3. factors that are likely to affect safety and efficacy; 4. occurrence of dizziness, balance disorders, ataxia, muscle relaxation-related adverse events, and falls as priority investigation items; 5. occurrence of psychiatric adverse events as priority investigation items (eg, aggression).

NCT ID: NCT03059329 Completed - Clinical trials for Primary Generalized Tonic-clonic Seizures

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures

FYC01S
Start date: August 1, 2016
Phase:
Study type: Observational

The objective of this study is to identify the following in adult epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa: 1. unknown adverse drug reactions (ADRs); 2. occurrence of ADRs; 3. factors that are likely to affect safety and efficacy; 4. occurrence of dizziness, balance disorders, ataxia, muscle relaxation-related adverse events, and falls as priority investigation items; 5. occurrence of psychiatric adverse events as priority investigation items (eg, aggression).

NCT ID: NCT03021018 Completed - Epilepsy Clinical Trials

A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting

Start date: February 6, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy of intravenous brivaracetam (BRV) compared to intravenous lorazepam (LZP) in subjects with epilepsy undergoing Epilepsy Monitoring Unit (EMU) evaluation who experience seizures that require prompt treatment.

NCT ID: NCT03007628 Completed - Schizophrenia Clinical Trials

Magnetic Seizure Therapy Versus Electroconvulsive Therapy for Schizophrenia

Start date: October 2016
Phase: N/A
Study type: Interventional

This trial attempts to evaluate the treatment efficacy of magnetic seizure therapy (MST) and its safety among schizophrenia patients. Half of the participants will be randomized to MST group, while the other half will be randomized to receive electroconvulsive therapy (ECT).

NCT ID: NCT03003156 Completed - Schizophrenia Clinical Trials

50 Hz vs. 25 Hz Magnetic Seizure Therapy for Schizophrenia

Start date: February 2016
Phase: N/A
Study type: Interventional

This trial attempts to investigate whether the dosage (frequency) has an effect on the treatment efficacy and cognitive outcomes of magnetic seizure therapy (MST) among schizophrenia patients. Half of the participants will be recruited to receive 25 Hz MST, while the other half will be recruited to 50 Hz MST.